Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 6,438 shares at $62.89 ($408K) on 2025-10-07, disclosed to the SEC on 2025-10-09.
Scheduled sale ($408k) by Executive VP AND CLO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $62.89 | 1,757 | $110K | 27.1% |
| 2 | $62.89 | 1,757 | $110K | 27.1% |
| 3 | $63.80 | 1,306 | $83K | 20.4% |
| 4 | $63.80 | 1,306 | $83K | 20.4% |
| 5 | $64.97 | 312 | $20K | 5.0% |
| Total | $63.36 avg | 6,438 |
| $408K |
| 100% |
| Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |
| PTCT | SELL | 2026-05-19 | $203K | — | Filing → |
| PTCT | SELL | 2026-05-12 | $280K | — | Filing → |